Meeting
2020 ASCO Virtual Scientific Program
Selpercatinib (LOXO-292) in patients with RET-mutant medullary thyroid cancer.
Authors
Manisha H. Shah
Ohio State University Comprehensive Cancer Center, Columbus, OH
Manisha H. Shah , Eric Jeffrey Sherman , Bruce Robinson , Benjamin J. Solomon , Hyunseok Kang , Jochen H. Lorch , Francis P. Worden , Marcia S. Brose , Sophie Leboulleux , Yann Godbert , Marie Meurer , John C. Morris III, Taofeek Kunle Owonikoko , Daniel Shao-Weng Tan , Oliver Gautschi , Jyoti D. Patel , Luxi Yang , Jennifer Kherani , Maria E. Cabanillas , Lori J. Wirth
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Clinical Trial Registration Number
NCT03157128
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3594)
DOI
10.1200/JCO.2020.38.15_suppl.3594
Abstract #
3594
Poster Bd #
324
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Selpercatinib efficacy and safety in patients with RET-altered thyroid cancer: A clinical trial update.
First Author: Eric Jeffrey Sherman
Poster
2021 ASCO Annual Meeting
Efficacy of selpercatinib after prior systemic therapy in patients with RET mutant medullary thyroid cancer.
First Author: Lori J. Wirth
Poster
2019 ASCO Annual Meeting
Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers.
First Author: Matthew H. Taylor
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Durable efficacy of selpercatinib in patients with RET fusion+ solid tumors, with a focus on GI tumors: LIBRETTO-001.
First Author: Vivek Subbiah